Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Polihexanide - SIFI

X
Drug Profile

Polihexanide - SIFI

Alternative Names: AKANTIOR; PHMB; Poliesanide; Polyhexamethylene biguanide hydrochloride - SIFI; Polyhexamethylene biguanide ophthalmic solution - SIFI; polyhexanide

Latest Information Update: 07 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SIFI
  • Class Antiparasitics; Disinfectants; Polymers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acanthamoeba infections; Keratitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acanthamoeba infections

Most Recent Events

  • 30 Sep 2024 SIFI receives a notice of allowance from the European Patent Office for 'formulation based on polyhexamethylene biguanide for use in the treatment of acanthamoeba keratitis and/or fungal infections'
  • 30 Sep 2024 SIFI has pending patent applications for patent application in USA, Canada, Mexico, South Korea, India, Australia, Japan and China for polyhexanide
  • 30 Sep 2024 Launched for Acanthamoeba infections (In adolescents, In adults) in Germany (Ophthalmic)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top